Cereno Scientific receives patent approval in US for use of drug candidate CS1
Cereno Scientific has received a Notice of Allowance for the company’s patent application titled “Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation” from the US Patent Office, which means that the Patent Office intends to grant the company’s patent application. The pending patent approval provides Cereno Scientific with intellectual property rights for the company’s treatment concept and use of its drug candidate, CS1, in the US.“It’s very gratifying to receive this information, which gives CS1